Abstract
Purpose: The traditional Chinese medicine (TCM), Sheng-xue-xiao-van (SXXB) is reported to be effective in treatment of thrombocytopenic purpura and chemotherapy-induced thrombocytopenia in clinical practices. The purpose of this study was to explore the functions of the SXXB Capsule in ovarian cancer in vitro.Methods: The toxicity of the medicine was measured using CCK8 method in ovarian cancer cell lines A2780 and OC-3-VGH and also the human ovarian epithelial cell line IOSE80. The cells were treated using the DMSO-diluted SXXB solution with the concentration levels at0, 3.125 and 6.25 μg/ml. Western blot was applied to measure the VEGFA proteins in each group. Later, the cells treated with 0 and 25μg/ml SXXB solution for 48h were collected for supernatant. Then HUVECs were co-cultured with the supernatant. Migration and tube formation assays were performed thereafter.Results: SXXB solution showed higher toxicity in ovarian cancer cells than in IOSE80. The protein levels of VEGFA were reduced as the SXXB concentrations increased in ovarian cancer cells but not in IOSE80. Migration and formed tubes were inhibited in HUVECs co-cultured with the supernatant collected from SXXB-treated ovarian cancer cells.Conclusion: The SXXB Capsule might inhibit the angiogenesis in ovarian cancer in vitro.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
